Protocol Ledger

NCT06636786 · Phase II · RECRUITING

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

Interventional Phase II clinical trial protocol NCT06636786 sponsored by University of North Carolina, Chapel Hill in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-25 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06636786
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06636786
Protocol FieldVerified Registry Value
NCT IdentifierNCT06636786
Consolidated Lead SponsorUniversity of North Carolina, Chapel Hill
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2025-03-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06636786
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
Indiana UniversityIndianapolis, INOpen Hospital Dossier ->
University of Kansas Medical CenterKansas City, KSOpen Hospital Dossier ->
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UNC Health across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI